Published in Am J Trop Med Hyg on May 01, 1979
New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother (1984) 2.32
In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother (1989) 1.53
Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob Agents Chemother (1988) 1.45
Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz (2009) 1.45
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1992) 1.40
Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother (1988) 1.30
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother (1998) 1.09
Enzyme immunoassay for evaluation of Toxoplasma gondii growth in tissue culture. J Clin Microbiol (1985) 1.05
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimicrob Agents Chemother (1990) 0.98
Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol (1999) 0.97
Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg (2010) 0.97
Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrob Agents Chemother (1989) 0.95
Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev (1995) 0.84
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease. Antimicrob Agents Chemother (2005) 0.81
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity. Antimicrob Agents Chemother (2015) 0.79
Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment. Can J Vet Res (1990) 0.75
Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani. Drug Des Devel Ther (2016) 0.75
ABC of AIDS: treatment of infections and antiviral agents. Br Med J (Clin Res Ed) (1987) 0.75
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis (1980) 5.57
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
The compromised host and infection. II. Deep fungal infection. J Infect Dis (1969) 4.63
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
AIDS commentary. Toxoplasmic encephalitis. J Infect Dis (1988) 4.14
Toxoplasmosis in pregnancy. Clin Infect Dis (1994) 3.91
Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol (1980) 3.81
In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun (1971) 3.81
Control of carcinogenesis: a possible role for the activated macrophage. Science (1972) 3.69
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol (1983) 3.53
Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA (1984) 3.48
Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms. J Immunol (1969) 3.29
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol (1989) 3.20
A role for activated macrophages in resistance to infection with Toxoplasma. Infect Immun (1972) 3.12
IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases. J Lab Clin Med (1968) 3.07
Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med (1996) 2.97
Toxoplasmosis in the compromised host. Ann Intern Med (1976) 2.96
False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol (1997) 2.84
Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol (1976) 2.79
Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice. J Immunol (1988) 2.77
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis (2001) 2.74
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol (1981) 2.61
Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis (1971) 2.58
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother (1991) 2.56
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis (1990) 2.49
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice. J Immunol (1990) 2.47
The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol (1972) 2.46
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis (1993) 2.45
Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol (1972) 2.44
Detection and characterization of membrane antigens of Toxoplasma gondii. J Immunol (1980) 2.43
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37
IgM antibodies in acute toxoplasmosis. I. Diagnostic significance in congenital cases and a method for their rapid demonstration. Pediatrics (1968) 2.36
Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis (1971) 2.34
Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis (1984) 2.27
Antigenemia in recently acquired acute toxoplasmosis. J Infect Dis (1980) 2.20
Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol (1990) 2.19
Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother (1988) 2.16
Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med (1973) 2.15
Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother (1974) 2.14
Gamma-M-fluorescent treponemal antibody in the diagnosis of congenital syphilis. N Engl J Med (1969) 2.10
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis (2001) 2.09
Toxoplasmosis in the adult--an overview. N Engl J Med (1978) 2.06
Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis (1996) 2.04
IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr (1981) 2.04
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis (1991) 2.04
Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis (1981) 2.03
Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. J Clin Microbiol (1981) 2.03
Tropical fish aquariums. A source of Mycobacterium marinum infections resembling sporotrichosis. JAMA (1970) 2.00
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis (1980) 1.99
Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. J Clin Microbiol (1990) 1.95
Dissociation of effector functions in populations of activated macrophages. Nature (1977) 1.95
Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis (1986) 1.93
The RNA of toxoplasma gondii. Proc Soc Exp Biol Med (1970) 1.93
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Genetic control of murine resistance to Toxoplasma gondii. Infect Immun (1978) 1.91
Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science (1968) 1.88
A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods (1979) 1.87
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.86
Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol (1976) 1.86
Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol (1997) 1.85
Strain-dependent differences in murine susceptibility to toxoplasma. Infect Immun (1976) 1.85
False-positive anti-Toxoplasma fluorescent-antibody tests in patients with antinuclear antibodies. Appl Microbiol (1971) 1.85
Pulmonary infection in the compromised host: part I. Am Rev Respir Dis (1976) 1.82
The role of thymus-derived lymphocytes in the in vitro activation of macrophages to kill Listeria monocytogenes. J Immunol (1973) 1.82
Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol (1981) 1.81
Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis (1993) 1.80
Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet (1983) 1.80
Comparison of methods for quantitating antigen-specific immunoglobulin M antibody with a reverse enzyme-linked immunosorbent assay. J Clin Microbiol (1983) 1.79
Biology of Toxoplasma gondii. AIDS (1993) 1.79
Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. J Clin Microbiol (1996) 1.78
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76
IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol (1995) 1.76
Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol (2000) 1.75
A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology (1991) 1.73
Functional and quantitative alterations in T lymphocyte subpopulations in acute toxoplasmosis. J Infect Dis (1984) 1.73
In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother (1992) 1.72
Studies on the regulation of lymphocyte reactivity by normal and activated macrophages. Cell Immunol (1977) 1.70
Studies on the serodiagnosis of toxoplasmic lymphadenitis. Clin Infect Dis (1995) 1.69
Role of specific immunoglobulin E in diagnosis of acute toxoplasma infection and toxoplasmosis. J Clin Microbiol (1993) 1.68
Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells. J Immunol (1991) 1.68
Effect of antibiotics on the immune response. Am J Med (1982) 1.67
Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr (1993) 1.67
Mitogen- and antigen-specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect Immun (1994) 1.66
Demonstration of Candida precipitins in human sera by counterimmunoelectrophoresis. Lancet (1972) 1.66
Isolation of the encysted form of Toxoplasma gondii from human skeletal muscle and brain. N Engl J Med (1965) 1.64
Toxoplasmic encephalitis in patients with AIDS. Infect Dis Clin North Am (1988) 1.64
Strain typing of Toxoplasma gondii: comparison of antigen-coding and housekeeping genes. J Parasitol (2000) 1.63
Toxoplasmosis in the adult. Bull N Y Acad Med (1974) 1.63
Activity of human blood leukocytes against Toxoplasma gondii. J Infect Dis (1979) 1.63
TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol (1999) 1.63
Expression, characterization, and serologic reactivity of recombinant surface antigen P22 of Toxoplasma gondii. J Clin Microbiol (1992) 1.62